Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Abscopal Effect of Radiotherapy and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma: Results of the International GHSG Phase II Aern Trial

Paul J. Bröckelmann, Ina Bühnen, Josée M Zijlstra, Stephan Mathas, Katrin S Roth, Maria Garcia-Marquez, Christian Sillaber, Julia Meissner, Alexander Fossa, Richard Greil, Karolin Trautmann-Grill, Johannes Rosenbrock, Wouter Plattel, Hans A Schlösser, Carsten Kobe, Michael Fuchs, Peter Borchmann, Christian Baues

Blood (2024) 144 (Supplement 1): 4428.

https://doi.org/10.1182/blood-2024-202113

Published: 2024

Journal Articles

Targeted Treatment Additions Ibrutinib + Bortezomib + R-CHOP for Higher-Risk DLBCL: Efficacy, Feasibility and Molecular Signatures for Future Treatment Decisions

Blood (2024) 144 (Supplement 1): 6188.

https://doi.org/10.1182/blood-2024-207123

Published: 2024

Journal Articles

Comprehensive Analysis of Treatment Related Morbidity and Progression -Free Survival in the GHSG Phase III HD21 Trial

Blood (2023) 142 (Supplement 1): 3057.

https://doi.org/10.1182/blood-2023-188720

Published: 2023

Journal Articles

Nivolumab and AVD in Early-Stage Unfavorable Hodgkin Lymphoma: Follow-up Analysis of the Randomized GHSG Phase II Nivahl Trial

Paul J Bröckelmann, Ina Bühnen, Julia Meissner, Karolin Trautmann-Grill, Peter Herhaus, Teresa V Halbsguth, Valdete Schaub, Andrea Kerkhoff, Stephan Mathas, Matthias Bormann, Andreas Dickhut, Helen Kaul, Michael Fuchs, Carsten Kobe, Christian Baues, Peter Borchmann, Andreas Engert, Bastian von Tresckow

Blood (2022) 140 (Supplement 1): 1753–1755.

https://doi.org/10.1182/blood-2022-168846

Published: 2022

Journal Articles

Treatment Related Morbidity in Patients with Classical Hodgkin Lymphoma: Results of the Ongoing, Randomized Phase III HD21 Trial By the German Hodgkin Study Group

Blood (2022) 140 (Supplement 1): 771–773.

https://doi.org/10.1182/blood-2022-165917

Published: 2022

Journal Articles

High-Dose Chemotherapy and Autologous Stem Cell Transplant in Elderly and Fit Primary CNS Lymphoma Patients - a Multicenter Study By the Cooperative PCNSL Study Group (MARTA study)

Blood (2022) 140 (Supplement 1): 1773–1774.

https://doi.org/10.1182/blood-2022-162157

Published: 2022

Journal Articles

Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1

Blood (2020) 136 (25): 2851–2863.

https://doi.org/10.1182/blood.2020008553

Published: 2020

Includes: Supplemental data

Journal Articles

Efficacy and Safety of Nivolumab and AVD in Early-Stage Unfavorable Hodgkin Lymphoma: Extended Follow-up from the GHSG Phase II Nivahl Trial

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-138413

Published: 2020

Journal Articles

Nivolumab and AVD for Early-Stage Unfavorable Hodgkin Lymphoma (NIVAHL)

Blood (2019) 134 (Supplement_1): 236.

https://doi.org/10.1182/blood-2019-122406

Published: 2019

Journal Articles

Abscopal Effect of Radiotherapy and Nivolumab in Relapsed or Refractory Hodgkin Lymphoma (AERN): An International Multicenter Single-Arm Two-Stage Phase II GHSG Trial

Paul J Bröckelmann, MD, Annette Plütschow, Richard Greil, MD, Josée M Zijlstra, MD PhD, Timothy Illidge, MD PhD, Alexander Fosså, MD PhD, Julia Meissner, MD, Andreas Zimmermann, MD, Stephan Mathas, MD, Felicitas Thol, MD, Michael Fuchs, MD, Andreas Engert, MD, Christian Baues, MD

Blood (2019) 134 (Supplement_1): 1547.

https://doi.org/10.1182/blood-2019-124351

Published: 2019

Journal Articles

Autocrine LTA signaling drives NF-κB and JAK-STAT activity and myeloid gene expression in Hodgkin lymphoma

Linda von Hoff, Eva Kärgel, Vedran Franke, Erik McShane, Kathrin W. Schulz-Beiss, Giannino Patone, Nikolai Schleussner, Marina Kolesnichenko, Norbert Hübner, Oliver Daumke, Matthias Selbach, Altuna Akalin, Stephan Mathas, Claus Scheidereit

Blood (2019) 133 (13): 1489–1494.

https://doi.org/10.1182/blood-2018-08-871293

Published: 2019

Includes: Supplemental data

Journal Articles

Pharmacological restoration and therapeutic targeting of the B-cell phenotype in classical Hodgkin lymphoma

Blood (2017) 129 (1): 71–81.

https://doi.org/10.1182/blood-2016-02-700773

Published: 2017

Includes: Supplemental data

Journal Articles

Restoring the Lost B-Cell Phenotype Renders Classical Hodgkin's Lymphoma Susceptible to B-Cell-Targeting Therapies

Nina Rosa Neuendorff, MD, Jing Du, PhD, Yong Yu, PhD, Jens Peter von Kries, PhD, Stephan Mathas, MD, Bernd Dörken, Prof., Soyoung Lee, PhD, Clemens A. Schmitt, MD Prof

Blood (2016) 128 (22): 1094.

https://doi.org/10.1182/blood.V128.22.1094.1094

Published: 2016

Journal Articles

Targeted Beacopp Variants in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma: Final Analysis of a Randomized Phase II Study

Peter Borchmann, MD, Dennis A. Eichenauer, MD, Annette Pluetschow, Heinz Haverkamp, Stefanie Kreissl, MD, Michael Fuchs, Martin Soekler, Johannes C. Hellmuth, MD, Julia Meissner, MD, Stephan Mathas, Karolin Behringer, MD, Markus Dietlein, Carsten Kobe, Volker Diehl, MD, Andreas Engert

Blood (2015) 126 (23): 580.

https://doi.org/10.1182/blood.V126.23.580.580

Published: 2015

Journal Articles

Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma

Blood (2015) 125 (1): 124–132.

https://doi.org/10.1182/blood-2014-08-594507

Published: 2015

Includes: Supplemental data

Journal Articles

Targeted Beacopp Variants In Patients With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma: Interim Results Of a Randomized Phase II Study

Peter Borchmann, MD, Dennis A. Eichenauer, MD, Annette Plütschow, PhD, Stefanie Kreissl, MD, Michael Fuchs, MD, Martin Soekler, MD, Nicole Engel, MD, Julia Meissner, MD, Stephan Mathas, Karolin Behringer, MD, Markus Dietlein, MD, Carsten Kobe, MD, Volker Diehl, MD, Andreas Engert, MD

Blood (2013) 122 (21): 4344.

https://doi.org/10.1182/blood.V122.21.4344.4344

Published: 2013

Journal Articles

Serum/Glucocorticoid-Regulated Kinase 1 (SGK1) Is a Prominent Target Gene of the Transcriptional Response to Cytokines In Multiple Myeloma and Supports the Growth of Myeloma Cells

Unn-Merete Fagerli, MD, PhD, Thorsten Stühmer, PhD, Toril Holien, Randi Utne Holt, PhD, Ove Bruland, PhD, Manik Chatterjee, MD, John Shaughnessy, Jr, PhD, Stephan Mathas, MD, Anders Sundan, MD, Ralf C Bargou, MD, Bernd Dörken, MD, Magne Borset, MD, PhD, Martin Janz, MD

Blood (2010) 116 (21): 1915.

https://doi.org/10.1182/blood.V116.21.1915.1915

Published: 2010

Journal Articles

High-Level Expression of Mastermind-Like 2 (MAML2) Contributes to Aberrant Activation of the NOTCH Signaling Pathway In Human Lymphomas

Karl Köchert, Stephan Kreher, Jon C Aster, MD, PhD, Motoo Kitagawa, Korinna Jöhrens, Ioannis Anagnostopoulos, Franziska Jundt, MD, PD, Harald Stein, MD, Martin Janz, MD, Bernd Dörken, MD, Stephan Mathas, MD

Blood (2010) 116 (21): 2685.

https://doi.org/10.1182/blood.V116.21.2685.2685

Published: 2010

Journal Articles

Aberrant expression of the Th2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts T reg cells via regulation of MIP-3α

Björn Lamprecht, Stephan Kreher, Ioannis Anagnostopoulos, Korinna Jöhrens, Giovanni Monteleone, Franziska Jundt, Harald Stein, Martin Janz, Bernd Dörken, Stephan Mathas

Blood (2008) 112 (8): 3339–3347.

https://doi.org/10.1182/blood-2008-01-134783

Published: 2008

Includes: Supplemental data

Journal Articles

A Novel Notch Pathway Inhibitor Blocks Osteoclast Activity and Synergistically Induces Apoptosis with the Proteasome Inhibitor Bortezomib in Multiple Myeloma Cells.

Franziska Jundt, MD, Rolf Schwarzer, Phd, Martin Kaiser, MD, Oezlem Acikgoez, MD, Ulrike Heider, MD, Stephan Mathas, MD, Robert Preissner, Phd, Orhan Sezer, MD, Bernd Dorken, MD

Blood (2007) 110 (11): 1522.

https://doi.org/10.1182/blood.V110.11.1522.1522

Published: 2007

NARROW

Abscopal Effect of Radiotherapy and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma: Results of the International GHSG Phase II Aern Trial

Targeted Treatment Additions Ibrutinib + Bortezomib + R-CHOP for Higher-Risk DLBCL: Efficacy, Feasibility and Molecular Signatures for Future Treatment Decisions

Comprehensive Analysis of Treatment Related Morbidity and Progression -Free Survival in the GHSG Phase III HD21 Trial

Nivolumab and AVD in Early-Stage Unfavorable Hodgkin Lymphoma: Follow-up Analysis of the Randomized GHSG Phase II Nivahl Trial

Treatment Related Morbidity in Patients with Classical Hodgkin Lymphoma: Results of the Ongoing, Randomized Phase III HD21 Trial By the German Hodgkin Study Group

High-Dose Chemotherapy and Autologous Stem Cell Transplant in Elderly and Fit Primary CNS Lymphoma Patients - a Multicenter Study By the Cooperative PCNSL Study Group (MARTA study)

Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1

Efficacy and Safety of Nivolumab and AVD in Early-Stage Unfavorable Hodgkin Lymphoma: Extended Follow-up from the GHSG Phase II Nivahl Trial

Nivolumab and AVD for Early-Stage Unfavorable Hodgkin Lymphoma (NIVAHL)

Abscopal Effect of Radiotherapy and Nivolumab in Relapsed or Refractory Hodgkin Lymphoma (AERN): An International Multicenter Single-Arm Two-Stage Phase II GHSG Trial

Autocrine LTA signaling drives NF-κB and JAK-STAT activity and myeloid gene expression in Hodgkin lymphoma

Pharmacological restoration and therapeutic targeting of the B-cell phenotype in classical Hodgkin lymphoma

Restoring the Lost B-Cell Phenotype Renders Classical Hodgkin's Lymphoma Susceptible to B-Cell-Targeting Therapies

Targeted Beacopp Variants in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma: Final Analysis of a Randomized Phase II Study

Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma

Targeted Beacopp Variants In Patients With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma: Interim Results Of a Randomized Phase II Study

Serum/Glucocorticoid-Regulated Kinase 1 (SGK1) Is a Prominent Target Gene of the Transcriptional Response to Cytokines In Multiple Myeloma and Supports the Growth of Myeloma Cells

High-Level Expression of Mastermind-Like 2 (MAML2) Contributes to Aberrant Activation of the NOTCH Signaling Pathway In Human Lymphomas

Aberrant expression of the Th2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts T reg cells via regulation of MIP-3α

A Novel Notch Pathway Inhibitor Blocks Osteoclast Activity and Synergistically Induces Apoptosis with the Proteasome Inhibitor Bortezomib in Multiple Myeloma Cells.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only